Several hypotheses suggest that type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD), and antidiabetic medications may influence cognitive function in these patients.
Objective
This study aims to provide a comprehensive evaluation of the impact of single and combination antidiabetic therapies on cognitive function in patients with both AD and T2DM.
Methods
We analyzed data from the National Alzheimer's Coordinating Center (NACC), covering a 17-year period from June 2005 to August 2022. This study included 3234 patients with both AD and T2DM. After applying exclusion criteria, 964 patients were analyzed using propensity score matching and a generalized linear mixed model. Patients were categorized based on their longitudinal use of oral antidiabetic medications.
Results
Based on the 964 patients’ cohort, the study found that patients receiving metformin with sulfonylureas (RR = 1.105 [1.022, 1.195], p = 0.013) and metformin with a dipeptidyl peptidase 4 inhibitor (DPP-4i) (RR = 1.132 [1.021, 1.256], p = 0.019) experienced a significantly slower decline in MMSE scores over time when compared to patients receiving metformin with thiazolidinediones (TZD).
Conclusions
This study demonstrates that combination therapies involving metformin with sulfonylureas or DPP-4i are associated with a slower rate of cognitive decline compared to metformin with TZD in patients with AD and T2DM. These findings provide novel evidence for the long-term cognitive benefits of specific antidiabetic therapies and offer valuable insights for clinical decision-making in this dual-affected population.
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health2022; 7: e105–e125.
3.
GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet2023; 402: 203–234.
4.
JansonJLaedtkeTParisiJE, et al.Increased risk of type 2 diabetes in Alzheimer disease. Diabetes2004; 53: 474–481.
5.
Muñoz-JiménezMZaarktiAGarcía-ArnésJA, et al.Antidiabetic drugs in Alzheimer's disease and mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord2020; 49: 423–434.
6.
YuJTXuWTanCC, et al.Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry2020; 91: 1201–1209.
7.
SluggettJKKoponenMBellJS, et al.Metformin and risk of Alzheimer's disease among community-dwelling people with diabetes: a national case-control study. J Clin Endocrinol Metab2020; 105: dgz234.
8.
KimYGJeonJYKimHJ, et al.Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus sulfonylureas: a real-world population-based cohort study. J Clin Med2018; 8: 28.
9.
HsuCCWahlqvistMLLeeMS, et al.Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis2011; 24: 485–493.
10.
GoldMAldertonCZvartau-HindM, et al.Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord2010; 30: 131–146.
11.
WuCYOukMWongYY, et al.Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status. Alzheimers Dement2020; 16: 1663–1673.
12.
BesserLMKukullWATeylanMA, et al.The revised national Alzheimer's coordinating center's neuropathology form-available data and new analyses. J Neuropathol Exp Neurol2018; 77: 717–726.
13.
BesserLKukullWKnopmanDS, et al.Version 3 of the national Alzheimer's coordinating center's uniform data set. Alzheimer Dis Assoc Disord2018; 32: 351–358.
14.
MorrisJCWeintraubSChuiHC, et al.The uniform data set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord2006; 20: 210–216.
15.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
16.
Ravona-SpringerRLuoXSchmeidlerJ, et al.The association of age with rate of cognitive decline in elderly individuals residing in supporting care facilities. Alzheimer Dis Assoc Disord2011; 25: 312–316.
17.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
18.
StuartEALeeBKLeacyFP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol2013; 66: S84–S90.e81.
19.
HoDImaiKKingG, et al.Matchit: nonparametric preprocessing for parametric causal inference. J Stat Softw2011; 42: 1–28.
20.
BrooksMEKristensenKvan BenthemKJ, et al.glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. R J2017; 9: 378–400.
21.
MichailidisMMoraitouDTataDA, et al.Alzheimer's disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes. Int J Mol Sci2022; 23: 2687.
22.
LuoANingPLuH, et al.Association between metformin and Alzheimer's disease: a systematic review and meta-analysis of clinical observational studies. J Alzheimers Dis2022; 88: 1311–1323.
23.
NewbyDLindenABFernandesM, et al.Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. BMJ Open Diabetes Res Care2022; 10: e003036.
24.
XueYXieX. The association between metformin use and risk of developing severe dementia among AD patients with type 2 diabetes. Biomedicines2023; 11: 2935.
25.
SecnikJXuHSchwertnerE, et al.The association of antidiabetic medications and Mini-mental state examination scores in patients with diabetes and dementia. Alzheimers Res Ther2021; 13: 197.
26.
ChenKCChungCHLuCH, et al.Association between the use of dipeptidyl peptidase 4 inhibitors and the risk of dementia among patients with type 2 diabetes in Taiwan. J Clin Med2020; 9: 660.
27.
PerryTLahiriDKSambamurtiK, et al.Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res2003; 72: 603–612.
28.
AnFMChenSXuZ, et al.Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: studies in vivo and in vitro. Neuroscience2015; 300: 75–84.
29.
KosarajuJGaliCCKhatwalRB, et al.Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology2013; 72: 291–300.
30.
KorneliusELinCLChangHH, et al.DPP-4 inhibitor linagliptin attenuates Aβ-induced cytotoxicity through activation of AMPK in neuronal cells. CNS Neurosci Ther2015; 21: 549–557.
31.
PearceNJArchJRClaphamJC, et al.Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter. Metabolism2004; 53: 1322–1330.
32.
ZhangQQLiWSLiuZ, et al.Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: a meta-analysis and systematic review. Medicine (Baltimore)2020; 99: e19378.
33.
WuCYIskanderCWangC, et al.Association of sulfonylureas with the risk of dementia: a population-based cohort study. J Am Geriatr Soc2023; 71: 3059–3070.
34.
OrkabyARChoKCormackJ, et al.Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. Neurology2017; 89: 1877–1885.
35.
SeaquistERMillerMEFonsecaV, et al.Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. J Diabetes Complications2013; 27: 485–491.
36.
RyanCMFreedMIRoodJA, et al.Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care2006; 29: 345–351.
37.
TangXBrintonRDChenZ, et al.Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes. BMJ Open Diabetes Res Care2022; 10: e002894.
38.
GaleaEFeinsteinDLLacombeP. Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice. Diabetologia2006; 49: 2153–2161.
39.
MasciopintoFDi PietroNCoronaC, et al.Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis2012; 3: e448.
40.
ZulloARDupreyMSSmithRJ, et al.Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents. Diabetes Obes Metab2022; 24: 247–256.
41.
KimWJNohJHHanK, et al.The association between second-line oral antihyperglycemic medication on types of dementia in type 2 diabetes: a nationwide real-world longitudinal study. J Alzheimers Dis2021; 81: 1263–1272.
42.
WuC-YShapiroLOukM, et al.Glucose-lowering drugs, cognition, and dementia: the clinical evidence. Neurosci Biobehav Rev2022; 137: 104654.
43.
YangWLuoHMaY, et al.Effects of antihypertensive drugs on cognitive function in elderly patients with hypertension: a review. Aging Dis2021; 12: 841–851.
44.
HuZWangLMaS, et al.Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement (N Y)2018; 4: 542–555.
45.
GentreauMRukhGMiguetM, et al.The effects of statins on cognitive performance are mediated by low-density lipoprotein, C-reactive protein, and blood glucose concentrations. J Gerontol A Biol Sci Med Sci2023; 78: 1964–1972.
46.
SamarasKMakkarSCrawfordJD, et al.Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney memory and ageing study. Diabetes Care2020; 43: 2691–2701.
47.
SheenYJSheuWH. Association between hypoglycemia and dementia in patients with type 2 diabetes. Diabetes Res Clin Pract2016; 116: 279–287.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
